CoChat

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

Open access
Klein, Nicola P., Stockwell, Melissa S., Demarco, Maria, Gaglani, Manjusha, Kharbanda, Anupam B., Irving, Stephanie A., Rao, Suchitra, Grannis, Shaun J., Dascomb, Kristin, Murthy, Kempapura, Rowley, Elizabeth A., Dalton, Alexandra F., DeSilva, Malini B., Dixon, Brian E., Natarajan, Karthik, Stenehjem, Edward, Naleway, Allison L., Lewis, Ned, Ong, Toan C., Patel, Palak, Konatham, Deepika, Embi, Peter J., Reese, Sarah E., Han, Jungmi, Grisel, Nancy, Goddard, Kristin, Barron, Michelle A., Dickerson, Monica, Liao, I-Chia, Fadel, William F., Yang, Duck-Hye, Arndorfer, Julie, Fireman, Bruce, Griggs, Eric P., Valvi, Nimish R., Hallowell, Carly, Zerbo, Ousseny, Reynolds, Sue, Ferdinands, Jill, Wondimu, Mehiret H., Williams, Jeremiah, Bozio, Catherine H., Link-Gelles, Ruth, Azziz-Baumgartner, Eduardo, Schrag, Stephanie J., Thompson, Mark G., Verani, Jennifer R. · 2022 · MMWR. Morbidity and Mortality Weekly Report
Cited by 179

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

† The data in these analyses come from 306 ED and UC clinics and 164 hospitals.§ The study period at Baylor Scott and White Health began on September 11, 2021.VE against COVID-19-associated ED and UC encounters was substantially lower during the Omicron predominant period than the B.1.617.2 (Delta) predominant period among adolescents aged 12-17 years, with no significant protection ≥150 days after dose 2 during Omicron predominance.However, in adolescents aged 16-17 years, VE during the Omicron predominant period increased to 81% ≥7 days after a third booster dose.During the full study period, including pre-Delta, Delta, and Omicron predominant periods, VE against laboratory-confirmed COVID-19-associated hospitalization among children aged 5-11 years was 74% 14-67 days after dose 2, with wide CIs that included zero.Among adolescents aged 12-15 and 16-17 years, VE 14-149 days after dose 2 was 92% and 94%, respectively; VE ≥150 days after dose 2 was 73% and 88%, respectively.All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations, including a booster dose for those aged 12-17 years.VISION Network VE methods have been previously published (7).In brief, eligible medical encounters were defined as ED and UC encounters and hospitalizations among persons aged ≥5 years with a COVID-19-like illness diagnosis ¶ who had received SARS-CoV-2 molecular testing (primarily by reverse transcription-polymerase ¶ Medical events with an encounter or discharge code consistent with COVID-19like illness were included, using International Classification of Disease, Ninth Revision and International Classification of Diseases, Tenth Revision (ICD-10).Four categories of codes were considered: 1) acute respiratory illness, including COVID-19, respiratory failure, viral or bacterial pneumonia, asthma exacerbation, influenza, and viral illness not otherwise specified; 2) nonrespiratory COVID-19-like illness diagnoses including cause-unspecified gastroenteritis, thrombosis, and acute myocarditis; 3) respiratory signs and symptoms consistent with COVID-19-like illness, including hemoptysis, cough, dyspnea, painful respiration, or hypoxemia; 4) signs and symptoms of acute febrile illness.One code in any of the four categories was sufficient for inclusion.Clinician-ordered molecular assays (e.g., real-time reverse transcription-polymerase chain reaction) for SARS-CoV-2 occurring ≤14 days before to <72 hours after the encounter date were included.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15585/mmwr.mm7109e3

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 5

  1. Reis, 2021, Effectiveness of BNT162b2 vaccine against Delta variant in adolescents., N Engl J Med, 385, 2101, 10.1056/NEJMc2114290 · DOI
  2. Olson, 2022, Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents., N Engl J Med, 386, 713, 10.1056/NEJMoa2117995 · DOI · Paper page
  3. Lutrick, 2021, Interim estimate of vaccine effectiveness of BNT162b2 (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection among adolescents aged 12–17 years—Arizona, July–December 2021., MMWR Morb Mortal Wkly Rep, 70, 1761, 10.15585/mmwr.mm705152a2 · DOI
  4. Thompson, 2021, Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings., N Engl J Med, 385, 1355, 10.1056/NEJMoa2110362 · DOI · Paper page
  5. Britton, 2022, Association of COVID-19 vaccination with symptomatic SARS-CoV-2 infection by time since vaccination and Delta variant predominance., JAMA 2022., 10.1001/jama.2022.2068 · DOI

Cited by

See all 179

Metadata

Authors
Klein, N. P., Stockwell, M. S., Demarco, M., Gaglani, M., Kharbanda, A. B., Irving, S. A., Rao, S., Grannis, S. J., Dascomb, K., Murthy, K., Rowley, E. A., Dalton, A. F., DeSilva, M. B., Dixon, B. E., Natarajan, K., Stenehjem, E., Naleway, A. L., Lewis, N., Ong, T. C., Patel, P., Konatham, D., Embi, P. J., Reese, S. E., Han, J., Grisel, N., Goddard, K., Barron, M. A., Dickerson, M., Liao, I.-C., Fadel, W. F., Yang, D.-H., Arndorfer, J., Fireman, B., Griggs, E. P., Valvi, N. R., Hallowell, C., Zerbo, O., Reynolds, S., Ferdinands, J., Wondimu, M. H., Williams, J., Bozio, C. H., Link-Gelles, R., Azziz-Baumgartner, E., Schrag, S. J., Thompson, M. G., & Verani, J. R.
Venue
MMWR. Morbidity and Mortality Weekly Report
Published
2022-03-04
Volume
71
Issue
9
Pages
352-358
ISSN
  • 0149-2195 (ISSN-L)
  • 1545-861X
OpenAlex
W4214628111
Cited by
179
References
5
FWCI
19.96
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022. https://app.cochat.ai/papers/10.15585/mmwr.mm7109e3
The paper
Klein, N. P., Stockwell, M. S., Demarco, M., Gaglani, M., Kharbanda, A. B., Irving, S. A., Rao, S., Grannis, S. J., Dascomb, K., Murthy, K., Rowley, E. A., Dalton, A. F., DeSilva, M. B., Dixon, B. E., Natarajan, K., Stenehjem, E., Naleway, A. L., Lewis, N., Ong, T. C., . . . Verani, J. R. (2022). Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7109e3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.